RxDoctor Payments Data

Brian Thompson, MD

Neurology · Greenville, SCNPI 1821024993

Payments from drug & device makers

$10,932in general payments, 2019–2025

Across 662 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Acadia Pharmaceuticals Inc$1K
  • AbbVie$935
  • Biohaven Pharmaceuticals, Inc.$762
  • Neurocrine Biosciences, Inc.$756
  • Biohaven Pharmaceutical Holding Company Ltd.$750
  • plus $5K from 52 others

What the payments were for

  • Speaking & faculty fees$1271%
  • Food & beverage$10,49196%
  • Education$3133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.142$2,002
Acadia Pharmaceuticals Inc87$1,078
AbbVie(2 entities)67$935
Biohaven Pharmaceuticals, Inc.38$762
Neurocrine Biosciences, Inc.36$756
Biohaven Pharmaceutical Holding Company Ltd.41$750
Novartis28$394
EMD Serono, Inc.20$299
UCB, Inc.12$280
Livanova USA, Inc.5$272
Amgen(2 entities)13$268
Acorda Therapeutics, Inc10$183
Sanofi8$171
Lundbeck LLC8$165
Eisai Inc.9$164
Merz Pharmaceuticals, LLC6$153
Kyowa Kirin, Inc.9$136
AstraZeneca7$133
Pfizer11$130
Portola Pharmaceuticals, LLC1$126
Genentech USA, Inc.6$124
Supernus Pharmaceuticals, Inc.9$122
Sunovion Pharmaceuticals Inc.7$115
Argenx US, Inc.3$98
Biogen7$94
Lilly USA, LLC7$93
Otsuka America Pharmaceutical, Inc.4$72
Avanir Pharmaceuticals, Inc.5$66
Bristol Myers Squibb4$65
Banner Life Sciences, LLC3$65
Grifols USA, LLC4$63
Neurelis, Inc.3$57
Amneal Pharmaceuticals LLC4$56
Takeda Pharmaceuticals U.S.A., Inc.2$55
Avion Pharmaceuticals3$51
GE HealthCare3$48
TG Therapeutics, Inc.2$45
Ipsen Biopharmaceuticals, Inc2$42
Mallinckrodt Enterprises LLC2$40
MDD US Operations, LLC2$33
Johnson & Johnson2$33
E.r. Squibb & Sons, L.L.C.2$30
Abbott2$29
Impel Pharmaceuticals Inc.2$26
CSL Behring1$26
ANI Pharmaceuticals, Inc.1$25
Hospira, Inc.1$23
Akcea Therapeutics, Inc.1$23
Scilex Pharmaceuticals Inc.1$22
SK Life Science, Inc.1$18
Upsher-smith Laboratories LLC1$18
Jazz Pharmaceuticals Inc.1$18
Tanabe Pharma America, Inc.1$17
Adamas Pharmaceuticals, Inc.1$15
Assertio Therapeutics, Inc.1$14
Boston Scientific1$14
Merz North America, Inc.1$13
Zyla Life Sciences, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,932 in reported general payments places this provider in the 75th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$394,319
Medicare patients
540
Services billed
23,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine22$127,291
Nurtec OdtRimegepant Sulfate39$40,542
Aimovig AutoinjectorErenumab-Aooe28$26,482
Emgality PenGalcanezumab-Gnlm11$7,438
Gabapentin182$5,447
RytaryCarbidopa/Levodopa19$5,386
Levetiracetam58$2,491
Dimethyl Fumarate20$1,849
Baclofen67$1,450
Pregabalin47$1,360
Levetiracetam ErLevetiracetam13$1,269
Divalproex Sodium21$979
Lamotrigine17$708
Acetazolamide ErAcetazolamide11$677
Carbidopa-LevodopaCarbidopa/Levodopa18$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$2,002$127,29122 claims
PfizerNurtec Odt$130$40,54239 claims
Amneal Pharmaceuticals LLCRytary$56$5,38619 claims
Upsher-smith Laboratories LLCTopiramate$18$18115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 270 neurology providers in South Carolina.

Other neurology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →